196 results on '"Podolanczuk, Anna J."'
Search Results
2. MUC5B, telomere length and longitudinal quantitative interstitial lung changes: the MESA Lung Study
3. Design and rationale for the prospective treatment efficacy in IPF using genotype for NAC selection (PRECISIONS) clinical trial
4. A Narrative Review of Real-World Data on the Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis
5. Interventions to Improve Quality of Life and Knowledge in Hypersensitivity Pneumonitis: A Survey of Clinician Practices and Perspectives
6. Practice patterns in reporting interstitial lung abnormality at a tertiary academic medical center
7. The symptoms evolution of long COVID‑19 (SE-LC19): a new patient-reported content valid instrument
8. Associations of Serum Adipokines With Subclinical Interstitial Lung Disease Among Community-Dwelling Adults The Multi-Ethnic Study of Atherosclerosis (MESA)
9. Overlap of Genetic Risk between Interstitial Lung Abnormalities and Idiopathic Pulmonary Fibrosis.
10. The Role of Inflammation and Fibrosis in ILD Treatment Decisions
11. Development and content validation of the Symptoms Evolution of COVID-19: a patient-reported electronic daily diary in clinical and real-world studies
12. Cough-Specific Quality of Life Predicts Disease Progression Among Patients With Interstitial Lung Disease: Data From the Pulmonary Fibrosis Foundation Patient Registry
13. Resequencing Study Confirms That Host Defense and Cell Senescence Gene Variants Contribute to the Risk of Idiopathic Pulmonary Fibrosis
14. Genetics and Genomics of Pulmonary Fibrosis: Charting the Molecular Landscape and Shaping Precision Medicine.
15. The Role of Inflammation and Fibrosis in Interstitial Lung Disease Treatment Decisions.
16. Nintedanib and symptoms of fibrotic lung disease: a glimmer of hope for patients living with pulmonary fibrosis
17. Thematic analysis to explore patients’ experiences with long COVID-19: a conceptual model of symptoms and impacts on daily lives
18. Pulmonary Fibrosis Stakeholder Summit: A Joint National Heart, Lung, and Blood Institute, Three Lakes Foundation, and Pulmonary Fibrosis Foundation Workshop Report
19. Approach to Clinical Trials for the Prevention of Pulmonary Fibrosis
20. Defining the pathway to timely diagnosis and treatment of interstitial lung disease: a US Delphi survey
21. Prevalence, Risk Factors, and Outcomes of Adult Interstitial Lung Abnormalities: A Systematic Review and Meta-Analysis
22. Bystander No More: Small Airway Involvement in Idiopathic Pulmonary Fibrosis.
23. Collagen biomarkers and subclinical interstitial lung disease: The Multi-Ethnic Study of Atherosclerosis
24. Frailty and maximal exercise capacity in adult lung transplant candidates
25. Incidence of Interstitial Lung Abnormalities: The MESA Lung Study
26. The Future of Clinical Trials in Idiopathic Pulmonary Fibrosis
27. Obstructive Sleep Apnea and Longitudinal Changes in Interstitial Lung Imaging and Lung Function: The MESA Study
28. Idiopathic pulmonary fibrosis: state of the art for 2023
29. Radiographic Lung Abnormalities in First-Degree Relatives of Patients with Different Subtypes of Pulmonary Fibrosis
30. Additional file 3 of Design and rationale for the prospective treatment efficacy in IPF using genotype for NAC selection (PRECISIONS) clinical trial
31. Additional file 1 of Design and rationale for the prospective treatment efficacy in IPF using genotype for NAC selection (PRECISIONS) clinical trial
32. Additional file 4 of Design and rationale for the prospective treatment efficacy in IPF using genotype for NAC selection (PRECISIONS) clinical trial
33. Additional file 2 of Design and rationale for the prospective treatment efficacy in IPF using genotype for NAC selection (PRECISIONS) clinical trial
34. Validity and Reliability of the Fatigue Severity Scale in a Real-World Interstitial Lung Disease Cohort.
35. Reliability and Validity of an Instrument of COVID-19 Patient-Reported Symptoms in Outpatients
36. Cough-Specific Quality of Life Predicts Disease Progression Among Patients With Interstitial Lung Disease
37. Pioneering Research Driving Progress toward a Cure for Interstitial Lung Disease (ILD): Introduction to the AJRCCM Special Issue on ILD (Part 2).
38. MUC5B, telomere length and longitudinal quantitative interstitial lung changes: the MESA Lung Study
39. Associations of hiatus hernia with CT-based interstitial lung changes: the MESA Lung Study
40. High-Attenuation Areas on Chest Computed Tomography and Clinical Respiratory Outcomes in Community-Dwelling Adults
41. Obstructive Sleep Apnea and Subclinical Interstitial Lung Disease in the Multi-Ethnic Study of Atherosclerosis (MESA)
42. Serum Matrix Metalloproteinase-7, Respiratory Symptoms, and Mortality in Community-Dwelling Adults. MESA (Multi-Ethnic Study of Atherosclerosis)
43. Occupational Exposures and Subclinical Interstitial Lung Disease. The MESA (Multi-Ethnic Study of Atherosclerosis) Air and Lung Studies
44. Patient-centered Outcomes in Idiopathic Pulmonary Fibrosis Clinical Trials
45. Patient experience of symptoms and impacts of COVID-19: a qualitative investigation with symptomatic outpatients
46. Associations of Monocyte Count and Other Immune Cell Types with Interstitial Lung Abnormalities
47. Clinical characteristics associated with small airways disease in systemic sclerosis
48. Inequity and the Interstitium: Pushing Back on Disparities in Fibrosing Lung Disease in the United States and Canada
49. A reliable and valid measure of COVID-19 patient-reported symptoms in outpatients: the Symptoms Evolution of COVID-19 (SE-C19) instrument
50. Watching an Evolution in Progress, Cutting-Edge Research Transforming Outcomes in Interstitial Lung Disease: Introduction to an AJRCCM Special Issue.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.